Neurological rehabilitation
What studies of neurological rehabilitation found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 5 of 7 findings are C.
7 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Neurological rehabilitation might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Neurological rehabilitation · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Breathlessness1 study · 47 people took part in neurological rehabilitation Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (47 in all).
Studies with no comparison group55 in the study · 47 with outcome data · 2 week on-site intervention; subsequent 8-week digital app support · delivered 5 days per week, full-time, day-based
Breathlessness improved.
The evidence is very uncertain about the effect of neurological rehabilitation on breathlessness in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (47 in all)
See the 1 study
-
- People in the study
- 55 in the study · 47 with outcome data
- Dose
- delivered 5 days per week, full-time, day-based
- Outcome
- Mod. Medical Research Council Dyspnea Scale modified Medical Research Council dyspnea scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 47 people took part in neurological rehabilitation Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (47 in all).
Studies with no comparison group55 in the study · 47 with outcome data · 2 week on-site intervention; subsequent 8-week digital app support · delivered 5 days per week, full-time, day-based
Fatigue improved.
The evidence is very uncertain about the effect of neurological rehabilitation on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (47 in all)
See the 1 study
-
- People in the study
- 55 in the study · 47 with outcome data
- Dose
- delivered 5 days per week, full-time, day-based
- Outcome
- Fatigue-severity-scale-7 Fatigue Severity Scale-7
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 47 people took part in neurological rehabilitation Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (47 in all).
Studies with no comparison group55 in the study · 47 with outcome data · 2 week on-site intervention; subsequent 8-week digital app support · delivered 5 days per week, full-time, day-based
Low mood or anxiety improved.
The evidence is very uncertain about the effect of neurological rehabilitation on low mood or anxiety in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (47 in all)
See the 1 study
-
- People in the study
- 55 in the study · 47 with outcome data
- Dose
- delivered 5 days per week, full-time, day-based
- Outcome
- Anxiety hospital anxiety and depression scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 47 people took part in neurological rehabilitation Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (47 in all).
Studies with no comparison group55 in the study · 47 with outcome data · 2 week on-site intervention; subsequent 8-week digital app support · delivered 5 days per week, full-time, day-based
No clear change in cognition (brain fog).
The evidence is very uncertain about the effect of neurological rehabilitation on cognition (brain fog) in long COVID. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (47 in all)
See the 1 study
-
- People in the study
- 55 in the study · 47 with outcome data
- Dose
- delivered 5 days per week, full-time, day-based
- Outcome
- MoCA blind montreal cognitive assessment
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 47 people took part in neurological rehabilitation Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (47 in all).
Studies with no comparison group55 in the study · 47 with outcome data · 2 week on-site intervention; subsequent 8-week digital app support · delivered 5 days per week, full-time, day-based
Daily functioning improved.
The evidence is very uncertain about the effect of neurological rehabilitation on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (47 in all)
See the 1 study
-
- People in the study
- 55 in the study · 47 with outcome data
- Dose
- delivered 5 days per week, full-time, day-based
- Outcome
- Functional disability modified COVID-19 Yorkshire Rehabilitation Screening
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 47 people took part in neurological rehabilitation Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (47 in all).
Studies with no comparison group55 in the study · 47 with outcome data · 2 week on-site intervention; subsequent 8-week digital app support · delivered 5 days per week, full-time, day-based
Overall symptoms improved.
The evidence is very uncertain about the effect of neurological rehabilitation on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (47 in all)
See the 1 study
-
- People in the study
- 55 in the study · 47 with outcome data
- Dose
- delivered 5 days per week, full-time, day-based
- Outcome
- Symptom severity modified COVID-19 Yorkshire Rehabilitation Screening
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 47 people took part in neurological rehabilitation Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (47 in all).
Studies with no comparison group55 in the study · 47 with outcome data · 2 week on-site intervention; subsequent 8-week digital app support · delivered 5 days per week, full-time, day-based
No clear change in quality of life.
The evidence is very uncertain about the effect of neurological rehabilitation on quality of life in long COVID. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (47 in all)
See the 1 study
-
- People in the study
- 55 in the study · 47 with outcome data
- Dose
- delivered 5 days per week, full-time, day-based
- Outcome
- EQ-5D-5L—Index value EuroQol-5 dimensions-5 level
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Worse symptoms or a flare | 1 study |
All papers
- Evaluation of a multidisciplinary neurological rehabilitation program for the post-COVID-19 condition.2026 · no comparison group · 55 in the study · 47 with outcome data
- Cognitive-behavioral therapy for patients with post-COVID-19 condition (CBT-PCC): a feasibility trial.2024 · no comparison group · 64 in the study · 51 started · 63 with outcome data
Summary
This single-group, uncontrolled trial examined feasibility, acceptance, and effectiveness of a CBT-based group program (CBT-PCC) added to routine inpatient neurological rehabilitation for post-COVID-19 condition. It recruited 64 inpatients with a history of mild COVID-19 fulfilling WHO criteria at Kliniken Schmieder Konstanz and Gailingen, Germany. CBT-PCC comprised eight modules of 60 min over four weeks. Participants who attended at least one session (n = 51) completed on average 6.43 of eight modules; 13 (20.3%) attended no session. One participant did not complete pre-intervention assessment and 22 did not complete post-intervention assessment; ITT analysis used n = 63. Post-intervention was after a maximum of four weeks or at discharge. Session evaluation totals ranged from 3.01 to 3.49. At least one adverse event was reported by 85.4% and severe/extremely distressing events by 29.3%. Among pre-post measures, fatigue fell (FSS mean difference −0.38, p = 0.012, dav = 0.33); helplessness fell (−1.08, p = 0.004, dav = 0.39), and acceptance (1.52, p = 0.002, dav = 0.43), perceived benefits (1.34, p < 0.001, dav = 0.49), and self-efficacy (0.25, p = 0.011, dav = 0.33) increased. Somatic symptom distress (p = 0.064), SSD-12 (p = 0.420), depression (p = 0.171), and anxiety (p = 0.175) showed no significant changes; other measures did not yield significant changes. No control group, small sample, and drop-out limit interpretation.
- How do people with long COVID utilize COVID-19 vaccination and rehabilitation services and what are their experiences with these services? results of a qualitative study with 48 participants from Germany.2024 · no comparison group · 48 in the study
Summary
This qualitative study explored how people with long COVID in Germany used and experienced COVID-19 vaccination and outpatient or inpatient rehabilitation. Forty-eight adults with long COVID participated: 25 in one-on-one interviews and 23 in four focus groups. Participants were recruited through university hospital websites, social media, and respondents’ networks. No treatment duration and no comparison group were reported; the study analysed interview and focus-group accounts. Thirty-five participants reported receiving a COVID-19 vaccination, and 16 reported using rehabilitation. Nine participants stated they developed long COVID despite vaccination before COVID-19. Ten participants reported vaccination reactions, and two reported severe side effects. Three participants experienced symptoms comparable to the acute phase of COVID-19; two reported externally visible symptoms; two reported very poor health and heart problems; one reported extrasystoles; and one interviewee was hospitalized with myocarditis. Two participants reported persistent deterioration of their long COVID symptoms after vaccination. Among rehabilitation users, four reported rehabilitation helped to improve their health situation and alleviate long COVID complaints, while four experienced rehabilitation as unhelpful or counterproductive. Two persons found the combination of inpatient rehabilitation and rehabilitation sport helpful, and two participants reported inpatient psychosomatic rehabilitation in which long COVID was not considered. The authors note heterogeneous experiences and high willingness to be vaccinated and to participate in rehabilitation.
- Neuropsychological rehabilitation program for patients with post-COVID-19 syndrome: a clinical experience.2021 · no comparison group · 50 with outcome data
Summary
This clinical experience describes an 8-week outpatient neurorehabilitation programme at Institut Guttmann for patients with post–COVID-19 syndrome. The programme combined respiratory therapy, physical therapy, and neuropsychological rehabilitation (mood intervention, compensatory strategies, and cognitive therapy); cognitive therapy was delivered at home with the Guttmann NeuroPersonalTrainer platform at 5 sessions/week of one-hour duration. Results are from 50 patients with no history of neurological disease who completed the programme. There was no control group; outcomes were compared before and after treatment. Measures included digit span, the Rey Auditory Verbal Learning Test (RAVLT), a formal phonemic fluency task (PMR), and the Hospital Anxiety and Depression Scale. In non-hospitalised patients, the text reports significant pre-post differences for backward digit span (P = .048; r = 0.32), RAVLT-learning (P = .004; r = 0.47), RAVLT-recall (P = .002; r = 0.5), RAVLT-recognition (P = .004; r = 0.46), HADS-anxiety (P = .021; r = 0.39), and HADS-depression (P = .046; r = 0.34). In hospitalised patients, it reports significant differences for RAVLT-learning (P = .005; r = 0.36), RAVLT-recall (P < .001; r = 0.5), RAVLT-recognition (P = .033; r = 0.27), PMR (P = .042; r = 0.25), HADS-anxiety (P = .002; r = 0.42), and HADS-depression (P = .001; r = 0.46). All patients performed better on memory tasks after treatment, and the likelihood of anxiety or depression symptoms decreased significantly. The paper did not report harms or withdrawals. The authors note that no control group limits extrapolation.
- [Sleep disorders and fatigue syndrome in long COVID syndrome: case-based experiences from neurological/sleep medicine rehabilitation].2022 · case report · 4 in the study
Summary
Four case examples from a neurological/sleep medicine rehabilitation clinic described adults after COVID-19 with Long-COVID/Post-COVID symptoms. The report included one 30-year-old woman, one 48-year-old woman, one 18-year-old and one 31-year-old; no comparison group and no randomisation were reported. Treatments were multimodal and individual: movement/sport/physiotherapy and slowly built circuit training in Fall 1 over seven weeks, plus melatonin 2 mg retardiert in the evening; neuropsychological therapy, sport therapy with circuit training, light walking and increasing walking distance in Fall 2 over eight weeks, plus regular melatonin 2 mg retardiert; sport, physiotherapy, ergotherapy and low-dose Mestinon plus antidepressants in Fall 3 over ten weeks; physiotherapy, ergotherapy, speech therapy, lamotrigine 50 mg and valproic acid 300 mg 3× daily in Fall 4 during a twelve-week stay. Reported outcomes included physical performance, heart rate, sleep fragmentation, sleep quality, neuropsychological tests, subjective performance, hypersensitivity and sleep-onset insomnia. Fall 1 reported improvement over seven weeks, heart rate reduction to 64/min and 80% improvement of baseline symptoms; sleep fragmentation reduced after three weeks of melatonin and sleep quality was satisfactory after six weeks. Fall 2 reported increased physical performance within eight weeks, return to 70% of baseline performance, and improved insomnia with melatonin. Fall 3 reported no substantial clinical improvement after ten weeks. Fall 4 reported improved hypersensitivity within ten weeks and complete resolution of sleep-onset insomnia within the twelve-week stay. Harms and withdrawals were not reported.
- Utilization frequency and patient-reported effectiveness of symptomatic therapies in post-COVID syndrome.2024 · how it is prescribed, safety only · 200 with outcome data
Summary
This single-cohort retrospective study with a follow-up survey investigated symptomatic treatment use and patient-reported improvement in post-COVID syndrome. It included 200 patients attending the post-COVID center of the University Hospital of Erlangen between December 2022 and July 2023, with symptoms persisting at least three months after SARS-CoV-2 infection; vaccine-related symptom onset was excluded. Baseline records captured symptomatic therapies from three months post-infection until presentation. A follow-up questionnaire was completed by 165 patients (response rate 82.5%), a mean 6.3 months (SD = 2.2) after initial consultation. Treatment duration was not reported. There was no control group; patients rated improvement within the same cohort for each therapy they used, using 0 = no improvement to 3 = very strong improvement. Among therapy users, strong to very strong improvement was reported by 12 of 38 for beta-blockers, 8 of 27 for antibiotics, 5 of 15 for plasmapheresis, and 8 of 73 for outpatient psychotherapy. Vitamins and nutritional supplements were rated 9 of 135. No between-group comparison was reported. Harms, side effects, worsening and withdrawals were not reported. The authors state that the study gives initial insights into utilization and patient-reported symptom improvement.
- Psychotherapy in patients with long/post-COVID - A systematic review on the feasibility, acceptability, safety, and efficacy of available and emerging interventions.2025 · systematic review
Summary
This systematic review asked whether psychotherapy for long/post-COVID has been studied and what is known about feasibility, acceptability, safety, and efficacy. It searched PubMed, PsycInfo, and Web of Science on February 8, 2024 and included 12 studies of people with long/post-COVID; reported sample sizes in the recorded data include 16, 30, 33, 44, 51, 57 per group, 63, 64, 123, and 224. Treatments were psychotherapy, mostly CBT-based, often delivered within multimodal rehabilitation; one RCT compared CBT for post-COVID fatigue with care as usual. The recorded data do not state treatment durations. Outcomes included fatigue, pain, dyspnea, anxiety, depression, quality of life, cognitive symptoms, and physical functioning. Many pre-post improvements were reported. In the RCT, between-group differences favored CBT for fatigue, physical functioning, somatic symptoms, social functioning, and concentration problems at T1 and T2 (Cohen’s d=0.74 at post-treatment; Cohen’s d = 0.65 at six-month follow-up). Some findings were not significant: Hasting et al. reported no significant improvement in fatigue or sleepiness; Huth et al. reported no significant improvement in somatic symptom distress, depression, anxiety, or psychobehavioral features; Hayden et al. found no significant improvement in pain or anxiety at 6-month follow-up. García-Molina et al. reported poorer performance at 6-month follow-up in the intervention group. Harms included adverse events in Huth et al. (85.4%; severe 29.3%) and Kuut et al. (8 during CBT; 20 during care as usual; no serious adverse events); Compagno et al. reported no adverse cardiovascular events or clinical complications, and Fontana et al. reported no adverse events. Dropouts included 20.3% in Huth et al., 13 % in Kuut et al., twelve in Páez et al., 3 in Hayden et al., and two in Hasting et al.
- Rehabilitation Strategies for Post-COVID-19 Syndrome: The Role of Physical Therapy in Addressing Long-Term Pulmonary, Musculoskeletal, and Neurological Complications2022 · review
Summary
This review examined evidence-based rehabilitation strategies for post-COVID-19 syndrome (long COVID). It does not report the number of patients, where they were treated, or a comparison group; the review itself had no comparison group. The review describes physical therapy approaches including pulmonary rehabilitation, resistance training, flexibility exercises, functional mobility training, balance and cognitive rehabilitation, tele-rehabilitation, and multidisciplinary coordination. Cited programmes included a 12-week aerobic training program and 12-week musculoskeletal rehabilitation programs. Outcomes described included lung function, respiratory discomfort, six-minute walk distance, peak VO2, muscle strength, functional independence, stiffness, pain, risk of falling, postural control, functional mobility scores, and cognitive test scores. The review reports that cited studies found diaphragmatic breathing improved lung function and reduced respiratory discomfort; a 12-week aerobic training program increased six-minute walk distance and peak VO2; resistance training improved muscle strength and functional independence; dynamic stretching decreased stiffness and pain; functional mobility training helped independence and reduced risk of falling; balance exercises increased postural control and decreased risk of falls; a systematic review found 20-30% improved respiratory efficiency; 12-week musculoskeletal rehabilitation programs improved functional mobility scores by 40%; neurological rehabilitation had a 50% reduction in risk of falling and a 30% improvement in cognitive test scores. No side effects or withdrawals were reported for the review. The authors state rehabilitation services are still limited, especially in rural and deprived areas, and that no adequate standardized rehabilitation protocols currently exist for clinicians.